Angiotensin IV Derivative · HGF / c-Met Nootropic · Oral Capsule · Protocol Guide
Dihexa: The Honest Cognitive Peptide Guide
Dihexa is an orally active angiotensin IV derivative studied as a synaptogenic, procognitive compound that works through the hepatocyte growth factor (HGF) and c-Met pathway. Its entire evidence base is preclinical, in rodents and cell models, with zero human trials. Part of that base has been retracted for image manipulation. This guide says all of that out loud.
- FDA Status
- Not Approved, 503A Compounded
- Pharmacy
- Optimal Balance Pharmacy (503A licensed)
- Medical Service
- RxPepsDirect, physician-supervised
- Access
- 28 U.S. States
Our promise: There is no human trial of Dihexa. Not one. The procognitive case is built entirely on rodent and cell studies, the most-cited mechanism paper was retracted in 2025 for manipulated images, and the company built on this molecule paid a multimillion-dollar settlement over the underlying research. We tell you that before we tell you anything else.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed June 8, 2026.On this page
Section 01
What Dihexa Actually Is
Dihexa, chemically N-hexanoic-Tyr-Ile-(6) aminohexanoic amide and also labeled PNB-0408, is a small synthetic molecule derived from angiotensin IV. It was built by Joseph Harding and colleagues at Washington State University, and later moved into a company called M3 Biotechnology, which became Athira Pharma. The starting point was an old observation: angiotensin IV fragments improve memory in animals but break down too fast and do not reach the brain. Dihexa was the chemically modified, metabolically stable, orally active version designed to fix both problems.
What makes Dihexa unusual is the oral, brain-penetrant design. Most peptides are destroyed in the gut and cannot cross the blood-brain barrier, which is why they are injected. The 2012 characterization study reported that Dihexa survives oral dosing, reaches the brain, and reverses memory deficits in scopolamine-treated and aged rats while driving new synapse formation in the hippocampus. That oral route is the entire reason Optimal Balance Pharmacy fills it as a capsule rather than an injection.
What Dihexa is not is just as important. It is not an approved drug. It is not a studied human therapy. It has no Phase 1, no Phase 2, no FDA review for cognition. The popular framing that it is "millions of times more potent than BDNF" traces back to lab synaptogenesis assays from the founding group, not to any human or clinical outcome. That number is a cell-culture comparison, not a measure of how much sharper you will feel.
0
Human clinical trials of Dihexa, in any indication, ever
2012
Year the orally active analog was first characterized in rats (J Pharmacol Exp Ther)
2025
Year the most-cited HGF/c-Met mechanism paper was retracted
503A
Pathway for U.S. compounded access under physician prescription
Section 02
Who It Is Actually For
Because there is no human trial, every "fit" below is an inference from animal models, not a tested indication. We grade them by how much preclinical support exists and how far the leap to a human user actually is. None of these are established uses.
| Profile | Primary Motivation | Evidence Basis | Fit |
|---|---|---|---|
| Age-Related Memory Decline | Support memory and synaptic connectivity as cognition slips | Rodent models of aging and Alzheimer's pathology improved on memory tasks. No human data. | Best Studied (Animal Only) |
| Cognitive Enhancement in Healthy Adults | Sharper focus, faster learning, peak mental performance | Popular use case with zero supporting trials in healthy humans. Pure extrapolation. | Speculative |
| Neurodegenerative Interest | Synapse support in Alzheimer's, Parkinson's, nerve injury | Mixed preclinical signals. Some positive rodent studies, at least one negative. | Experimental, Not Therapy |
| Athlete Subject to Anti-Doping Testing | Cognitive support during training and competition | Non-approved substance, captured by the WADA S0 catch-all category. | Treat as Prohibited |
| Active Psychosis or Schizophrenia | Any cognitive goal | Listed contraindication. A synaptogenic agent in an unstable psychiatric state is not appropriate. | Do Not Use |
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Section 03
How Dihexa Works
The proposed mechanism is that Dihexa engages the hepatocyte growth factor (HGF) and its receptor c-Met, a signaling system tied to cell growth, survival, and synapse formation. Read the next paragraph carefully, because the cleanest statement of this mechanism is the paper that was retracted.
HGF / c-Met Activation
The founding studies proposed that Dihexa binds HGF and potentiates c-Met receptor activity, switching on growth and survival signaling in neurons. This is the headline mechanism, and it is also the claim most damaged by the 2025 retraction.
Synaptogenesis
In hippocampal cell and slice work, Dihexa increased dendritic spines and new synaptic connections. The widely repeated BDNF-potency comparison comes from these in-vitro assays, not from any living human.
PI3K / AKT Signaling
An independent 2021 study in Alzheimer's-model mice reported that Dihexa acted through the PI3K/AKT pathway, reduced neuroinflammation, and restored memory in the water maze. This line of work was not from the original lab, which matters.
Oral, Brain-Penetrant
The practical hook is delivery. Dihexa was engineered to survive the gut and cross the blood-brain barrier, so it can be taken as a capsule. That is a real and unusual property for a peptide-derived molecule.
Section 04
What the Evidence Shows
Here is the actual record, in order, with no human trial anywhere in it. Read the strength column, not just the findings.
| Study | Design | Key Finding | Strength |
|---|---|---|---|
| McCoy 2012 (JPET) [1] | Preclinical, rats (scopolamine and aged models) | The orally active analog Dihexa reversed memory deficits in the Morris water maze and increased hippocampal synaptogenesis. | Foundational, Preclinical |
| Benoist 2014 (JPET) [2] | Cell and rodent, mechanism study | Proposed that Dihexa's procognitive effect depends on HGF/c-Met activation. This is the headline mechanism paper. | RETRACTED in 2025 [3] |
| Sun 2021 (Brain Sci) [4] | APP/PS1 Alzheimer's-model mice, independent lab | Dihexa restored spatial memory, raised synaptic protein, and reduced neuroinflammation via PI3K/AKT. Not from the original group. | Independent Replication, Animal |
| Wells 2024 (J Huntingtons Dis) [5] | 3-NP Huntington's-model rats, independent lab | Dihexa (PNB-0408) did NOT protect rats from the induced deficits. A clean negative result. | Negative Result, Animal |
| Ho & Nation 2018 (review) [6] | Systematic review of angiotensin IV cognition studies | Across rodent models of cognitive deficit, AngIV analogs including Dihexa generally improved memory tasks. Experimental animal evidence only. | Systematic Review, Preclinical |
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Section 05
The Retraction and Research-Integrity Problem
Most peptide guides skip this. We will not, because it is central to judging the evidence. The Dihexa story is tangled up with a documented case of research misconduct, and you should know the shape of it before you decide.
2025
Year the core HGF/c-Met mechanism paper was formally retracted
4+
Papers from the founding researcher flagged for image manipulation
Settled
The company built on this work resolved federal False Claims Act allegations in 2025
A central figure in the early Dihexa research, who went on to lead the company commercializing the molecule, was found to have altered images in her doctoral dissertation and in at least four published papers spanning the foundational work. The most-cited mechanism paper was retracted in 2025 as a result. The company itself resolved federal False Claims Act allegations tied to research that supported grant funding. These are facts about the integrity of the evidence, not a claim that Dihexa is dangerous.
Section 06
Realistic Expectations
Set expectations against the honest backdrop: there is no human timeline because there is no human study. The timeline below is built from the biology of synapse formation and from how users self-report, not from trial data. Hold it loosely.
Likely Nothing Obvious
Synapse remodeling is a slow biological process, not a stimulant hit. Many users report no clear change early. If you are chasing a same-day "smart drug" feeling, that expectation does not match the proposed mechanism.
Possible Subtle Signals
Some users describe easier word recall or sharper focus around this point. This is anecdote, not evidence, and a real placebo effect is expected with any nootropic. Treat early impressions with skepticism.
Proposed Repair Window
If Dihexa does what the rodent work suggests, accumulating synaptic changes would surface over this window rather than all at once. There is no human measurement confirming this in people.
Reassess With Prescriber
A natural checkpoint to take stock honestly. With no objective marker to track, the decision to continue, pause, or stop rests on your own functional sense and your prescriber's judgment.
Section 07
Dosing Protocol
There is no validated human dose, because there is no human trial. The schedule below reflects common compounded practice and the once-daily oral pattern used in animal work. Your RxPepsDirect physician sets and adjusts it.
| Context | Dose | Route / Frequency | Evidence Basis |
|---|---|---|---|
| Preclinical Models | Weight-based (animal) | Oral, once daily | Rodent Studies Only |
| RxPepsDirect Standard | 1 capsule (5 mg) | By mouth, once daily, morning | Compounded Practice |
| Higher Strength Capsule | 25 mg available | By mouth, once daily, only if directed | Prescriber-Directed Only |
| Human Validated Dose | Does not exist | No human trial has ever set one | No Human Data |
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Take one capsule by mouth in the morning. Morning dosing is the convention because some users report that later dosing disturbs sleep. There are no needles, no syringes, no units, and no reconstitution: Dihexa is an oral capsule by design. Because no human dose-response curve exists, more is not assumed to be better, and the decision to move above the starting capsule belongs to your prescriber.
Section 08
Ready to Start
0
Needles or reconstitution steps required
503A
Licensed pharmacy (Optimal Balance), physician-supervised
Overnight
FedEx shipping, capsules ready to take on arrival
Section 09
Safety and Side Effects
The honest safety statement is uncomfortable: Dihexa has no characterized human safety profile because it was never tested in people. Animal studies did not flag obvious toxicity at studied doses, but absence of animal alarms is not the same as human safety. Proceed with that understood.
| Consideration | Detail | Action |
|---|---|---|
| No human safety data | No trials means side effects, interactions, and long-term risk in people are unknown | Use only under physician supervision and report anything unusual. |
| Sleep disruption | Some users report trouble sleeping with later dosing | Take in the morning. Tell your prescriber if sleep is affected. |
| Growth-signaling pathway | HGF/c-Met and growth signaling are theoretical concerns for anyone with a cancer history | Disclose any cancer history so your prescriber can weigh it. |
| Active psychosis or schizophrenia | Listed contraindication for this category | Do not use. |
| Psychiatric medications | Interaction profile in humans is uncharacterized | Review all psychiatric medications with your prescriber first. |
| Pregnancy / lactation | No safety data | Avoid. |
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Section 10
Stacking
Pairs Well With
Semax / Selank
Nasal nootropic combo on a different mechanism (BDNF, catecholamines, GABA). A common cognitive pairing. No route conflict with an oral capsule.
NAD+
Cellular energy and mitochondrial support alongside the synaptic-connectivity angle. Different system, independent timing.
Methylene Blue
Mitochondrial and cognitive support, but mind the category contraindications (see below). Discuss timing and screening with your prescriber.
Avoid or Use Caution
SSRIs / SNRIs / MAO inhibitors with Methylene Blue
If Methylene Blue is in the stack, these combinations are auto-deny in this category for serotonin syndrome risk. This is a hard screen.
Cancer history (theoretical)
Growth-pathway signaling makes Dihexa a flag for anyone with a cancer history. Raise it before stacking anything.
Pregnancy / lactation
No safety data. Avoid.
Section 11
Pricing
Pharmacy: Medication
From $3.50 per capsule. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy. Finished oral capsules, FedEx overnight, ready to take.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation including history review, contraindication screening, protocol design, prescription writing, and follow-up. Billed by RxPepsDirect for the medical service only.
Section 12
Legal Access in 28 States
503A Licensed Pharmacy
Optimal Balance Pharmacy, U.S. licensed
Physician Prescription Required
Compounded medication, Rx only
Investigational Compound
Preclinical only, no FDA approval
Off-Label, Legal Practice
Standard and legal in U.S. medicine
Dihexa is an investigational compound. It has no FDA approval for any indication and was never carried into human trials for cognition. In the United States it is accessed through 503A patient-specific compounding under a physician prescription. The 503A pathway is the documented legal route for compounded peptide access. RxPepsDirect prescribers serve patients in 28 states. Note for athletes: as a non-approved substance, Dihexa falls under the World Anti-Doping Agency S0 catch-all and should be treated as prohibited in tested sport.
Section 13
Community Q&A
Has Dihexa ever been tested in humans?
No. There are no published human clinical trials of Dihexa, in any indication, at any dose. Every claim about memory, focus, or synapse growth comes from rodents and cell cultures. The human record is empty, and that is the most important thing to know.
Is the Dihexa research reliable?
Parts of it are not. The most-cited mechanism paper was retracted in 2025, a founding researcher was found to have manipulated images across several papers, and the company built on the molecule settled federal False Claims Act allegations. Some independent rodent studies do reproduce a procognitive effect, and at least one good study found no benefit. Preliminary and contested is the fair summary.
Is it really millions of times stronger than BDNF?
That number comes from synaptogenesis assays in a dish, run by the original lab, not from any human or even whole-animal cognitive result. It describes potency in a specific cell experiment. It is not a measure of how much sharper you will feel, and it leans on the part of the literature that was later questioned.
How do I take it, and is it injected?
It is an oral capsule, taken once daily, usually in the morning. Dihexa was specifically engineered to be orally active and cross into the brain, which is rare for a peptide. No needles, no reconstitution. Optimal Balance Pharmacy ships finished capsules ready to take.
Can athletes use it?
Treat it as prohibited. Dihexa is a non-approved investigational substance, and the WADA S0 category captures any pharmacological substance not approved for human use. Confirm with your governing body before any use in tested sport.
Section 14
The RxPepsDirect Model
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your Dihexa under a patient-specific prescription, USP <797> standards, and federal 503A oversight, dispensed as finished oral capsules.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your history, screens for contraindications including psychiatric and cancer history, designs your protocol, and writes your prescription. RxPepsDirect bills the $39 medical visit fee for this service.
Transparent Safety Communication
This guide states plainly that there is no human data, that the core mechanism paper was retracted in 2025, that the founding research has an integrity problem, and that the BDNF-potency claim is a cell-culture number. We do not hide limitations to make a sale.
Legal Access in 28 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription.
References
- McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2012. PMID: 23055539
- Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system (RETRACTED 2025). J Pharmacol Exp Ther. 2014. PMID: 25187433
- Benoist CC, Kawas LH, Zhu M, et al. Retraction notice to: The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2025. PMID: 40312093
- Sun X, Deng Y, Fu X, et al. AngIV-analog Dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway. Brain Sci. 2021. PMID: 34827486
- Wells RG, Azzam AF, Hiller AL, Sardinia MF. Effects of an angiotensin IV analog on 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats. J Huntingtons Dis. 2024. PMID: 38489193
- Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1-7): a systematic review of experimental studies. Neurosci Biobehav Rev. 2018. PMID: 29733881
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
Russian nootropic + anxiolytic nasal spray
Semax / Selank combo guide: ACTH-fragment cognition plus tuftsin-analog anxiolytic
Two heptapeptides in one spray. Semax adds focus, Selank adds calm. Russian clinical use. Non-stimulant, non-sedating, 14 to 21 day course.
TP-7 tuftsin analog (anxiolytic)
Selank protocol guide: tuftsin-analog anxiolytic, Russian RCT evidence, and the 14-day course
Russian clinical use for generalized anxiety. Non-sedating, no documented tolerance. Western replication is thin. RxPepsDirect prescribes the Semax/Selank combo spray.
Mitochondrial cognitive capsule (MB-5 to MB-25)
Methylene Blue guide: mitochondrial electron carrier, MAO-A inhibitor, the SSRI contraindication
Mitochondrial electron carrier at low dose, MAO-A inhibitor at any dose. SSRIs, SNRIs, MAOIs, TCAs are hard contraindications. Hormetic dose curve. Medication screening is mandatory.
Continue reading